GHRP-2 vs GHRP-6: A Growth Hormone Secretagogue Research Comparison
GHRP-2 and GHRP-6 are two of the founding members of the synthetic growth hormone-releasing peptide (GHRP) class — short peptide ghrelin-receptor agonists characterized in the late 1980s and early 1990s. Both bind the growth hormone secretagogue receptor (GHSR-1a), the same receptor activated by endogenous ghrelin, and both stimulate growth hormone release from anterior pituitary somatotrophs through a mechanism distinct from the GHRH-receptor pathway engaged by sermorelin, CJC-1295, and tesamorelin. For researchers studying the parallel GHRH and ghrelin axes that converge on GH secretion, the GHRP class provides a complementary set of research tools.
GHRP-2 and GHRP-6 are supplied for in vitro and animal-research applications only.
Quick reference
| Field | GHRP-2 | GHRP-6 |
|---|---|---|
| CAS | 158861-67-7 | 87616-84-0 |
| Sequence (6 aa) | D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH₂ | His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂ |
| Molecular weight | ~817.95 Da | ~872.99 Da |
| GHSR-1a affinity | High (nanomolar) | High (nanomolar) |
| Reported potency vs. ghrelin | Comparable | Comparable |
| Effect on appetite circuits | Modest | More pronounced |
| Form supplied | Lyophilized white powder | Lyophilized white powder |
Receptor pharmacology
Both GHRP-2 and GHRP-6 are agonists at the growth hormone secretagogue receptor type 1a (GHSR-1a), a G-protein-coupled receptor expressed on anterior pituitary somatotrophs, hypothalamic neurons, and a subset of peripheral tissues. GHSR-1a is the endogenous receptor for ghrelin, the stomach-derived 28-amino-acid acylated peptide that signals nutritional status to the brain.
Receptor activation engages Gαq, increases intracellular calcium via phospholipase C / IP3 signaling, and drives GH release from somatotroph granules. The GHSR-1a pathway is mechanistically distinct from the GHRH-receptor pathway (Gαs / cAMP / PKA): the two pathways converge on GH release downstream but use different upstream signaling cascades. This distinction is the basis for the well-characterized synergy between GHRH agonists (like sermorelin) and ghrelin-receptor agonists (like the GHRPs) in research models of integrated GH-axis stimulation. For background on the GHRH side, see the sermorelin vs CJC-1295 comparison.
Structural differences
GHRP-2 has the sequence D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH₂. Key features:
– The D-2-naphthylalanine (D-2-Nal) at position 2 is a non-natural aromatic residue
– Three D-amino acid residues (positions 1, 2, 5) confer protease resistance
– The C-terminal amide is preserved
GHRP-6 has the sequence His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂. Key features:
– Histidine at the N-terminus (rather than D-Ala)
– D-Trp at position 2 (rather than D-2-Nal)
– Two D-amino acids (positions 2 and 5)
– C-terminal amide preserved
The structural differences cluster at positions 1 and 2 — the N-terminal cap of the peptide. These positions are critical for receptor recognition; the differences explain the somewhat distinct binding profiles and downstream effects.
Receptor-binding profile differences
Both compounds bind GHSR-1a with nanomolar affinity. Published characterization indicates GHRP-2 is somewhat more potent at GH release per molar dose in animal models — this is the primary literature distinction between them.
GHRP-6, however, has been reported to produce more pronounced effects on appetite-related neural circuits in animal studies, attributed to its differential interaction with hypothalamic ghrelin-receptor signaling. The mechanistic explanation is not fully resolved but is consistent with biased agonism — different ligands at the same receptor producing different downstream signaling profiles.
For research designs:
– GHRP-2 is the standard tool when GH secretion is the primary readout
– GHRP-6 is more useful when ghrelin-circuit appetite-axis interaction is part of the research question
Pharmacokinetics
Both compounds have short circulating half-lives in animal models — minutes rather than hours. The D-amino acid substitutions provide protease resistance relative to endogenous ghrelin, but the small molecular size leads to rapid renal clearance. Most published animal-study work uses repeated administration or short-window readouts.
For sustained GHSR-1a engagement, the more recent ipamorelin and hexarelin compounds — also in the GHRP class — provide alternative pharmacokinetic profiles. For research designs requiring long-window receptor occupancy, MK-0677 (a small-molecule GHSR-1a agonist) is the typical research tool.
Preclinical animal-study findings
Reported findings for both compounds in the published preclinical literature include:
– Dose-dependent GH release in animal models with characterized somatotroph axis
– Synergistic GH release when co-administered with GHRH-receptor agonists (the GHRH + GHRP combination is the classic “maximal-stimulation” research design)
– Modulation of IGF-1 levels in sustained-dosing animal models
– Effects on appetite-axis circuits (more pronounced for GHRP-6)
– Receptor-binding characterization in pituitary and hypothalamic cell culture
None of these findings constitute evidence of safety or efficacy in humans.
CoA verification
For both compounds:
– HPLC purity ≥99.0% with chromatogram visible
– Mass spectrum confirming expected molecular weight within ±0.5 Da
– D-amino acid confirmation — D vs. L stereochemistry can be verified by chiral HPLC; substitution of L-isomers in any position changes the compound’s protease-resistance profile
– Net peptide content with counterion identified
– Lot number matching vial
The stereochemistry check is essential for both compounds. The D-amino acid substitutions are what define each peptide; replacing any D-residue with the L-isomer produces a different (and substantially less stable) compound.
Storage
Both compounds are supplied lyophilized. Pre-reconstitution: 2–8°C, dry, away from light; -20°C for archival storage. The D-amino acid composition provides good solid-state stability. Post-reconstitution: 2–8°C in multi-dose diluent, use within ~28 days.
The C-terminal lysine in both compounds can undergo slow oxidative degradation in solution; minimize air exposure during reconstitution.
Choosing between the two
- GH-axis stimulation as the primary readout — GHRP-2 is the standard choice owing to its somewhat higher reported per-molar potency
- Ghrelin-circuit appetite-axis research — GHRP-6 is the more appropriate tool owing to its more pronounced appetite-axis effects
- Comparator-pair designs — using both in parallel arms isolates the appetite-circuit-specific contribution while keeping GHSR-1a activation roughly constant
Summary
GHRP-2 and GHRP-6 are short synthetic hexapeptide ghrelin-receptor agonists that engage GHSR-1a to drive somatotroph GH release through a Gαq / IP3 / Ca²⁺ signaling pathway distinct from the GHRH-receptor pathway. They share comparable nanomolar receptor affinity but differ in N-terminal structure, with consequences for GH-release potency (GHRP-2 modestly higher) and appetite-circuit interaction (GHRP-6 more pronounced). Both serve as research tools for the ghrelin-receptor arm of the integrated GH-secretion axis.
Research Use Only. Not for use in or on humans or animals. Not a food, drug, cosmetic, or supplement.